Image

Study of the Characteristics of the Vascular Wall in Pediatric Age

Study of the Characteristics of the Vascular Wall in Pediatric Age

Recruiting
6-17 years
All
Phase N/A

Powered by AI

Overview

With this study, we want to investigate the characteristics of the blood vessel wall and study cardiovascular risk in children and adolescents, whether or not they have heart disease, by subjecting patient to a noninvasive diagnostic examination with an innovative medical device called VICORDER©.

Description

Cardiovascular (CV) disease remains the leading cause of death in adulthood in industrialized countries, and processes of vascular wall disruption are a key pathogenetic element of this. These processes can begin as early as childhood, contributing to CV risk in later ages.

In particular, increased arterial stiffness is an independent CV risk factor that is associated with increased mortality, and its measurement may influence therapeutic decisions. The clinical value of studying arterial stiffness is recognized by the European Network for Noninvasive Investigation of Large Arteries and the 2018 European Society of Cardiology guidelines on hypertension.

The method considered as the gold standard for measuring arterial stiffness is carotid-femoral Pulse Wave Velocity (PWV), which can be measured noninvasively. The stiffer the arterial wall, the more PWV increases; left ventricular afterload and systolic arterial pressure (SAP) increase, while diastolic arterial pressure (DAP) and coronary perfusion decrease. Increased afterload promotes left ventricular hypertrophy, with increased oxygen demands, and thus increased susceptibility to myocardial ischemia.In pediatric age, the most important CV risk factors include overweight and obesity, hypertension (which, between 0 and 18 years has a prevalence of 3-5%, alterations in glucose and lipid metabolism, diabetes mellitus, and kidney disease, especially chronic renal failure. These risk factors promote increased arterial stiffness and thus the risk of adverse events.Some typical pediatric vasculitides can also change the morpho-functional characteristics of the artery wall. For example, Kawasaki disease (KD) is a vasculitis of medium- and small-caliber vessels affecting the preschool child, whose most fearsome complication is coronary aneurysms, with the possibility of partial or total secondary obstruction. It can also be associated with myocardial infarction and ischemic heart disease, and, more generally, patients are exposed to increased CV morbidity. Alterations in the structure and function of the arterial wall are also observed in adults born preterm, in children with congenital heart disease, or undergoing chemo-radiotherapy treatment for neoplasia, and even subjects with systemic diseases, such as systemic lupus erythematosus. A picture of multisystem inflammation with major cardiovascular involvement, Multisystem Inflammatory Syndrome in Children (MIS-C), is a rare but potentially fatal complication of SARS-CoV-2 infection in children, in which endothelial damage plays a central pathogenetic role and its possible association with arterial stiffness has been postulated, but studies on it are few. Detecting increased arterial stiffness as early as in children and adolescents could have important clinical repercussions for the above.

On the one hand, it would make it possible to stratify patients according to CV risk, also with a view to personalized medicine. It could allow the identification of new associations between certain diseases or exposure to environmental factors and increased arterial stiffness. Finally, it would allow assessment of the effectiveness of therapies: treatment from the earliest stages of functional impairment could change the natural history of disease, and consequently CV morbidity and mortality at later ages. VICORDER© is a quick and easy-to-use oscillometric device for studying vascular function by measuring, among other parameters, PWV. Its use in noninvasive measurement of PWV has been studied and validated in both adults and children and adolescents. In particular, the validation study by Kracht et al. was conducted in 156 children between 6 and 18 years of age, with the finding of excellent intra- and inter-observer repeatability, ease of use and tolerability for patients, making it suitable for large-scale studies. The study by Thurn et al. was conducted on 1003 healthy patients between 6 and 18 years of age and established normal PWV values (by sex, age, and height) measured with VICORDER© in pediatric age.

The device takes the form of a series of cuffs, similar in every way to a traditional sphygmomanometer, connected to a computer for analysis. The test involves the serial inflation and deflation of these cuffs, using an automatic procedure similar to that of measuring blood pressure with a digital sphygmomanometer.

Eligibility

Inclusion Criteria:

  • Patients from 6 to 17 years of age (extremes included) being treated in the Outpatient Departments of Emergency Pediatrics or admitted to the Department of Emergency Pediatrics
  • Patient cooperation during the performance of the examination.
  • Obtaining informed consent from the parent/legal guardian

Exclusion Criteria:

  • Behavioral disorders or severe cognitive retardation, extreme agitation, or other factors that may impair the proper performance of the examination.
  • Anatomical alterations or presence of device or local pathology that conflicts with the placement of the VICORDER© cuffs.

Study details
    Cardiovascular Diseases

NCT06774586

IRCCS Azienda Ospedaliero-Universitaria di Bologna

23 January 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.